相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
Saar Gill et al.
IMMUNOLOGICAL REVIEWS (2015)
Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy
Zachary Zimmerman et al.
INTERNATIONAL IMMUNOLOGY (2015)
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
Christina Krupka et al.
BLOOD (2014)
New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape
Deepak Mittal et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
CAR T cells: driving the road from the laboratory to the clinic
Eleanor J. Cheadle et al.
IMMUNOLOGICAL REVIEWS (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Targeting T cells to tumor cells using bispecific antibodies
Stanley R. Frankel et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2013)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
Michele Cioffi et al.
CLINICAL CANCER RESEARCH (2012)
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA
Li Peng et al.
PLOS ONE (2012)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
Ines Herrmann et al.
PLOS ONE (2010)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg et al.
NATURE REVIEWS CANCER (2008)
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
S Offner et al.
MOLECULAR IMMUNOLOGY (2006)
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
P Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
分享论文
